Bionomics (NASDAQ:BNOX) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Bionomics (NASDAQ:BNOX) in a research report released on Wednesday morning, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Bionomics’ FY2024 earnings at ($2.99) EPS and FY2025 earnings at ($1.45) EPS.

Bionomics Trading Down 5.5 %

Shares of NASDAQ:BNOX opened at $0.78 on Wednesday. The firm’s 50 day simple moving average is $0.93 and its 200 day simple moving average is $1.07. Bionomics has a fifty-two week low of $0.65 and a fifty-two week high of $6.41.

Institutional Trading of Bionomics

An institutional investor recently bought a new position in Bionomics stock. Lynx1 Capital Management LP purchased a new stake in Bionomics Limited (NASDAQ:BNOX) during the third quarter, according to its most recent filing with the SEC. The firm purchased 815,512 shares of the company’s stock, valued at approximately $2,202,000. Bionomics accounts for approximately 1.5% of Lynx1 Capital Management LP’s portfolio, making the stock its 12th largest position. Lynx1 Capital Management LP owned approximately 9.99% of Bionomics at the end of the most recent quarter. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.